Emerging biotech companies sometimes lack all of the experience, expertise, or financial capital to successfully transition investigational drugs from research to a commercially profitable product. These companies need to secure a combination of sophisticated investors, partners, and expert consultants to...
Emerging biotech companies sometimes lack all of the experience, expertise, or financial capital to successfully transition investigational drugs from research to a commercially profitable product. These companies need to secure a combination of sophisticated investors, partners, and expert consultants to...
This blog explains how using the Gene Therapy Virtual Twin® Platform can help optimize dosing for patients
Streamlines drug development by using PBPK modeling to predict drug behavior in virtual populations, optimize clinical study design, assess drug-drug interactions, and support regulatory decisions.
Certara’s Simcyp® Biologics platform enables scientists to model and predict the pharmacokinetics and pharmacodynamics of biologics, enhancing drug development and safety assessments.
This blog provides 8 clinical pharmacology and pharmacokinetic considerations that you should know for oligonucleotide therapeutics.
Expertly written patient narratives, enhanced by CoAuthor, ensuring consistency, quality, and improving safety reporting.
Narratives are an integral part of medical writing. Sponsors sometimes need to prepare large batches of these deliverables in a short period while most traditional methods prove unsuccessful in providing both consistency and quality. This can lead to questions...
Abstract During a pandemic caused by a novel pathogen (NP), drug repurposing offers the potential of a rapid treatment response via a repurposed drug (RD) while more targeted treatments are developed. Five steps of model‐informed drug repurposing (MIDR) are discussed:...
© 2025 Certara. All Rights Reserved. | Legal | Privacy policy
